These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7897755)

  • 21. Evaluation of lorcainide in patients with symptomatic ventricular tachycardia.
    Somberg JC; Butler B; Flowers D; Keefe D; Torres V; Miura D
    Am J Cardiol; 1984 Aug; 54(4):43B-48B. PubMed ID: 6465046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Electrophysiologic effects of lorcainide on the accessory pathway in the Wolff-Parkinson-White syndrome.
    Kasper W; Treese N; Meinertz T; Jähnchen E; Pop T
    Am J Cardiol; 1983 Jun; 51(10):1618-22. PubMed ID: 6858867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.
    Somani P; Temesy-Armos PN; Leighton RF; Goodenday LS; Fraker TD
    Am Heart J; 1984 Dec; 108(6):1443-8. PubMed ID: 6507240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of flecainide and lorcainide in blood by means of TLC.
    Paw B; Przyborowski L
    Acta Pol Pharm; 1995; 52(1):5-7. PubMed ID: 8960234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lorcainide. A comparative trial with quinidine gluconate in patients with previously untreated ventricular arrhythmias.
    Falk RH; O'Brien JL
    Chest; 1984 Oct; 86(4):537-40. PubMed ID: 6383741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous and oral lorcainide: assessment of central nervous system toxicity and antiarrhythmic efficacy.
    Vlay SC; Mallis GI
    Am Heart J; 1986 Mar; 111(3):452-5. PubMed ID: 3953352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New directions in antiarrhythmic drug therapy: the development of a promising new agent, lorcainide.
    Somberg JC; Torres V
    Am J Cardiol; 1984 Aug; 54(4):1B. PubMed ID: 6465042
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparative electrophysiology of lorcainide and norlorcainide in the dog.
    Keefe DL; Kates RE; Winkle RA
    J Cardiovasc Pharmacol; 1984; 6(5):808-15. PubMed ID: 6209484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of noninvasive arrhythmia induction techniques with electrophysiologic studies and evaluation of lorcainide in patients with symptomatic ventricular tachycardia.
    Somberg JC; Butler B; Flowers D; Tepper D; Maguire W; Willens H; Keren G; Miura D
    Am J Cardiol; 1984 Aug; 54(4):49B-54B. PubMed ID: 6465047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of lorcainide, a new antiarrhythmic agent, on experimental cardiac arrhythmias].
    Fukuda H; Goto M; Kondo M; Uchigasaki T; Sekino Y
    Nihon Yakurigaku Zasshi; 1983 Feb; 81(2):115-26. PubMed ID: 6852683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic implications of lorcainide therapy in patients with normal and depressed cardiac function.
    Somani P; Fraker TD; Temesy-Armos PN
    J Clin Pharmacol; 1987 Feb; 27(2):122-32. PubMed ID: 3680563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of lorcainide, a new anti-arrhythmic agent.
    Lloyd EA; Workman LJ; Commerford PJ; Mabin TA
    S Afr Med J; 1981 Dec; 60(24):929-31. PubMed ID: 7302777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical pharmacokinetics of the newer antiarrhythmic agents.
    Gillis AM; Kates RE
    Clin Pharmacokinet; 1984; 9(5):375-403. PubMed ID: 6437721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effects of procainamide, tocainide and lorcainide on Na(+)-K(+)-ATPase in guinea pig heart preparations.
    Dzimiri N; Almotrefi AA
    Gen Pharmacol; 1991; 22(2):403-6. PubMed ID: 1647350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical course and outcome in class IC antiarrhythmic overdose.
    Köppel C; Oberdisse U; Heinemeyer G
    J Toxicol Clin Toxicol; 1990; 28(4):433-44. PubMed ID: 2176700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lorcainide kinetics and protein binding in patients with end-stage renal disease.
    Somani P; Simon V; Gupta RK; King P; Shapiro RS; Stockard H
    Int J Clin Pharmacol Ther Toxicol; 1984 Mar; 22(3):121-5. PubMed ID: 6715079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lorcainide disposition kinetics in arrhythmia patients.
    Kates RE; Keefe DL; Winkle RA
    Clin Pharmacol Ther; 1983 Jan; 33(1):28-34. PubMed ID: 6848296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistant ventricular arrhythmias treated with lorcainide, a new antiarrhythmic drug.
    Somani P; di Giorgi S
    Chest; 1980 Oct; 78(4):658-60. PubMed ID: 7418495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of SUN 1165, a new potent antiarrhythmic agent, on the kinetics of rate-dependent block of Na channels and ventricular conduction of extrasystoles.
    Hattori Y; Hidaka T; Aisaka K; Satoh F; Ishihara T
    J Cardiovasc Pharmacol; 1988 Apr; 11(4):407-12. PubMed ID: 2453743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Electrophysiologic effects of lorcainide (R 15889) in man].
    Touboul P; Atallah G; Kirkorian G
    Arch Mal Coeur Vaiss; 1981 Nov; 74(11):1333-40. PubMed ID: 6797372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.